Overview

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Status:
Not yet recruiting
Trial end date:
2027-06-20
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of blinatumomab.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Blinatumomab